AmoyDX Partners with SALU Genomics through Strategic Investment to Enhance Upstream Technology Capabilities
Xiamen, China – Amoy Diagnostics Co., Ltd. ("AmoyDX"), a leading molecular diagnostics company in China, has entered into a strategic partnership with SALU Genomics (Suzhou) Co., Ltd. ("SALU Genomics"), culminating in the signing of a Series B Capital Increase Agreement. As part of this agreement, AmoyDX will invest RMB 50 million in cash to subscribe to new shares in SALU Genomics. Post-transaction, AmoyDX will hold a 2.38% equity stake in SALU Genomics.
This investment round has also attracted attention from other renowned industry investment firms, including Jinyi Hulian Limited, a subsidiary of the international investment firm Index Ventures, known for its focus on the intersection of AI and life sciences.
SALU Genomics: Driving Innovation with Three Core Platforms
As a National High-Tech Enterprise and a recognized"Little Giant" specialist SME, SALU Genomics is dedicated to the independent R&D and manufacturing of high-end life science instruments and molecular testing platforms. The company has established a comprehensive technological architecture encompassing an upstream sequencing platform, a super-resolution spatial omics platform, and a solid-phase gene chip detection platform, aiming to promote the widespread application of domestic sequencing and spatial omics technologies in research and clinical translation.
Strategic Expansion for AmoyDX: From Clinical Diagnostics to Upstream Technology
AmoyDX,a domestic leader in molecular diagnostics with a long-standing focus on tumor precision detection, companion diagnostics, and molecular reagent development, is strategically extending its reach into upstream core technologies through this investment. This move aims to:
· Strengthen control over upstream technological sources and reduce dependency on imported sequencing platforms.
· Drive the clinical translation of innovative achievements, accelerating the productization of spatial omics and chip technologies.
· Create a closed-loop technological ecosystem, enhancing efficiency across the R&D to diagnostics pipeline.
AmoyDX stated that future collaboration with SALU Genomics would focus on integrated innovation in genomics, spatial omics, and precision diagnostics to advance China's precision medicine industry.
Jinyi Hulian: Backing 'Hard Tech' to Bolster China's Life Science Innovation
Commenting on the investment,Mr. Zheng Li, Executive President of Jinyi Hulian, noted the strong strategic synergy between AmoyDX and SALU Genomics, highlighting the combination of SALU's robust upstream R&D capabilities with AmoyDX's clinical translation and market strengths. He expressed Jinyi Hulian's continued commitment to supporting core technology-driven healthcare companies, facilitating broader import substitution and international expansion for China's life science sector.
Future Outlook
The deep integration of AI,genomics, and spatial omics is ushering precision medicine into a new era focused on deeper insights. AmoyDX's investment in SALU Genomics represents a critical step in strengthening its upstream strategy and a key layout for advancing domestic sequencing and spatial multi-omics technologies. Looking ahead, AmoyDX plans to collaborate with SALU Genomics and partners like Jinyi Hulian to promote core technology independence, clinical translation of results, and the globalization of medical innovation.
